Evaluation of racotumomab for the treatment of lung cancer: Meta-analysis of controlled trials of the CIM

Article

Abstract: Racotumomab is a therapeutic cancer vaccine entirely developed in Cuba and licensed in the country f

Palabras claves:

immunotherapy, Non-small cell lung cancer, Oncological vaccines, Racotumomab, Vaccinal treatment

Autores:

Alfonso S., Aliuska Frías, Ballesteros J., Carmen Elena Viada, Hernández M., Mabel Álvarez, Macías A.E., Martha M. Fors-López, Quintero J., Robaina M.

Fuentes:

scopus